TABLE 2.
Baseline | 48 mo | ||||
Treatment | n | Mean CIMT (95% CI), mm | n | Mean CIMT (95% CI), mm | Estimated changeb in CIMT (95% CI), mm/y |
Placebo | 275 | 0.7213 (0.7106-0.7319) | 217 | 0.7502 (0.7388-0.7619) | 0.0072 (0.0058-0.0086) |
o-CEE | 230 | 0.7268 (0.7152-0.7384) | 185 | 0.7591 (0.7465-0.7717) | 0.008 (0.0065-0.0095) |
t-E2 | 222 | 0.7176 (0.7058-0.7294) | 178 | 0.7488 (0.7359-0.7616) | 0.0077 (0.0061-0.0092) |
o-CEE, oral conjugated equine estrogens; t-E2, transdermal 17-β estradiol.
aDerived from Table 2 of reference 7.
bChange between baseline and 48 months as annual slope.